PATENT CLAIM ANALYSIS

Application Number: 16083750
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "253070"]

Abstract:
Methods of using the antipsychotic drug aripiprazole in treating a neurodegenerative disease such as Machado-Joseph disease/Spinocerebellar ataxia type 3 (MJD/SCA3) are disclosed. The methods comprise administering aripiprazole in an amount effect to decrease protein aggregates in the central nervous system and intracellular forms of pathogenic proteins such as mutant ataxin-3.

Claim (Index 18):
A method of reducing intracellular ataxin-3 levels comprising contacting a cell with an effective amount of aripiprazole.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 97.0
- Lexical Diversity: 1.17391
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14585607', '15761964', '15895877', '13936696', '15554679']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7653954700575848
- 35 USC 102 Novelty (BERT): 0.5246897910159081
- Combined Prediction Score: 0.7413249021534171
- Mean Citation Score: 262.901052
- Max Citation Score: 323.41345
- Similarity Product: 211.8304029528022

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test